Global NewsNews

Biocon Biologics partners with Sandoz Australia

Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate sustained access to these medications

Biocon Biologics Ltd (BBL), announced a five-year partnership with Sandoz (‘Sandoz’) which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million) and biosimilar Bevacizumab (market value of AUD$45 million) in Australia. 

THIS CAN BE YOUR ADVERTISEMENT

Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate sustained access to these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin3 – both biosimilars are available on the PBS and utilised for the treatment of various cancers.

The agreement was effective from January 1, 2024 and commercialisation commenced from February 1, 2024. 

Matt Erick, Chief Commercial Officer of Advanced Markets, Biocon Biologics, said, “Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our global partnership and growth strategy. This relationship is also a crucial step for patients in Australia, ensuring continued access to high-quality, affordable biosimilar medicines used in oncology.” 

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close